Xinru Liu

Xinru Liu

Auto-generated profile, based on publicly available information

Xinru Liu

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China (X.L., Z.W., C.H., Y.W., Y.T., Y.X., J.L., J.Z., C.J., J.D., X.D.).

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
XWXiaojie Wei
Xiaojie Wei
CLChengbin Liu
Chengbin Liu
HQHehe Qin
Hehe Qin
ZYZiwei Ye
Ziwei Ye
XLXinru Liu
Xinru Liu
SMShun Mao
Shun Mao

27 August 2023 in Journal of Alloys and Compounds
Verified
Journal Article
Closed access
JGJinrong Gao
Jinrong Gao
HBHe Bai
He Bai
XLXiao Ling
Xiao Ling
YYYunjiang Yang
Yunjiang Yang
XLXinru Liu
Xinru Liu
XZXiaowei Zhu
Xiaowei Zhu

1 March 2024 in Hypertension
Verified
Journal Article
Closed access
WLWenjie Li
Wenjie Li
ZWZhiyan Wang
Zhiyan Wang
CJChao Jiang
Chao Jiang
CHChang Hua
Chang Hua
YTYangyang Tang
Yangyang Tang
XDXin Du
Xin Du
BACKGROUND: To evaluate whether cancer modifies the effect of intensive blood pressure control on major cardiovascular outcomes. METHODS: Using data of the SPRINT (Systolic Blood Pressure Intervention Trial), we compared the risk of the composite outcomes of myocardial infarction, other acute coronary syndromes, stroke, heart failure, and cardiovascular death in patients with and without a history of cancer. Using Cox proportional hazards regression, we tested interactions between history of cancer and intensive blood pressure control on major cardiovascular outcomes. RESULTS: The study included a total of 9336 patients, with a mean age of 67.9±9.4 years, among whom 2066 (22.2%) were cancer survivors. Over a median follow-up of 3.2 years, 561 primary cardiovascular outcomes were observed. Cancer survivors had a similar risk of experiencing the primary outcome compared with patients without cancer after multivariable adjustment (adjusted hazard ratio, 0.94 [95% CI, 0.77–1.15]). Intensive blood pressure control reduced risk of the primary cardiovascular outcome similarly for cancer survivors (hazard ratio, 0.70 [95% CI, 0.51–0.97]) and patients without cancer (HR, 0.76 [95% CI, 0.63–0.93]; P for interaction 0.74). CONCLUSIONS: In SPRINT study, intensive blood pressure treatment reduced the risk of major cardiovascular events in cancer survivors to a similar extent to that of patients without cancer. Cancer history not requiring active treatment in last 2 years should not be an obstacle to intensive treatment of hypertension. This post hoc analysis should be considered as hypothesis-generating and merit further clinical trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01206062.

21 June 2017 in Plant Biotechnology Reports
Verified
Journal Article
Closed access
PDF file
LLLu Liu
Lu Liu
RZRui-Jie Zhang
Rui-Jie Zhang
WZWenjiao Zhu
Wenjiao Zhu
XLXin-Ru Liu
Xin-Ru Liu
KSKe Shi
Ke Shi
QYQing Yang
Qing Yang